Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 5-6, 2011, Pages 326-334

  Rönquist Nii, Yuko ^a   Eksborg, Staffan ^b   Axelson, Magnus ^a   Harmenberg, Johan ^b   Beck, Olof ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hexylamine adduct; Human serum; LC MS MS; Picropodophyllin

Indexed keywords

ACQUITY; ANALYTES; ANTI-CANCER AGENTS; GRADIENT ELUTION; HEXYLAMINE; HUMAN SERUM; INTER-ASSAY PRECISION; INTERNAL STANDARDS; ION TRANSITION; LC-MS/MS; LIMIT OF DETECTION; LIMIT OF QUANTIFICATIONS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MATRIX EFFECTS; MILLI-Q WATER; MOBILE PHASE; PICROPODOPHYLLIN; PODOPHYLLOTOXIN; POSITIVE MODE; PROTEIN PRECIPITATION; PROTON ADDUCTS; RETENTION TIME; SAMPLE PREPARATION; SELECTED REACTION MONITORING; SIGNAL TO NOISE; THEORETICAL VALUES; THERAPEUTIC DOSE;

ACETONITRILE; BODY FLUIDS; CHEMICAL ANALYSIS; ELECTROSPRAY IONIZATION; FORMIC ACID; IONIZATION; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; METHANOL; STANDARDS;

ISOMERS;

ACETONITRILE; HEXYLAMINE; PICROPODOPHYLLIN; PODOPHYLLIN; PODOPHYLLOTOXIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; ELECTROSPRAY; ELUTION; HUMAN; ISOMER; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY;

ADULT; AGED, 80 AND OVER; AMINES; ANIMALS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MICE; PODOPHYLLOTOXIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SWINE; TANDEM MASS SPECTROMETRY;

EID: 79451471914     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.12.017     Document Type: Article

References (11)

1. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cancer Res. 2004, 64:236.
2. Gualberto A., Pollak M. Curr. Drug Targets 2009, 10:923.
3. Pollak M. Nat. Rev. Cancer 2008, 8:915.
4. Zhao L., Liu Z.L., Fan P.C., et al. J. Sep. Sci. 2009, 32:1323.
5. Razuvaev A., Henderson B., Girnita L., Larsson O., Axelson M., Hedin U., Roy J. J. Vasc. Surg. 2007, 46:108.
6. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnailk R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Pharmaceut. Res. B 2000, 825:1551.
7. Food Drug Administration Guidance for Industry: Bioanalytical Methods Validation 2001, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD.
8. Gao S., Zhang Z.P., Karnes H.T. J. Chromatogr. B 2005, 825:98.
9. Tashima K., Kondo T., Meada C., Oda T., Hagimoto T., Tsukuda R., Yushimura T. J. Mass Spectrom. 2002, 37:631.
10. Mortier K.K.A., Zhang G., Van Peterghem C.H., Lambert W.E. J. Am. Soc. Mass Spectrom. 2004, 15:585.
11. Stefansson M., Sjöberg P.J.R., Markides K.E. Anal. Chem. 1996, 68:1792.